Vicuron Pharmaceuticals Appoints Cheryl A. Wenzinger to Board of Directors
September 17 2004 - 2:00AM
PR Newswire (US)
Vicuron Pharmaceuticals Appoints Cheryl A. Wenzinger to Board of
Directors Retired Deloitte & Touche Partner Will Also Oversee
Audit Committee KING OF PRUSSIA, Pa., Sept. 17
/PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq:
MICU; Nuovo Mercato) today announced that the Company has appointed
Cheryl A. Wenzinger to serve on its Board of Directors. Ms.
Wenzinger, a retired audit partner with Deloitte & Touche LLP,
will also oversee Vicuron's audit committee. "Cheryl brings a rare
and extremely valuable combination of over 30 years of general
financial accounting experience, focused audit committee expertise
and a solid overall business background," said George F. Horner,
III, President and CEO of Vicuron. "We are very pleased she has
agreed to join our board." While a partner at Deloitte & Touche
from 1984 to 2000, Ms. Wenzinger served as the lead client service
partner for numerous private and public companies predominantly
focused on health care, insurance and real estate. She has
significant SEC experience with equity and debt offerings and
regulatory reporting. She currently serves on the Board of Trustees
for Delta Dental Plan of Colorado, where she chairs the audit
committee and serves on the strategy and business ethics and
corporate compliance committees. She also was recently appointed to
the Deloitte & Touche Retired Partners Committee. A member of
the Board of Directors of Diversa Corporation since February of
2004, Ms. Wenzinger also serves as the financial expert on its
audit committee. From 1990 to 2000, Ms. Wenzinger was president of
the 8,300-member Colorado Society of CPAs. In this role, she formed
and chaired the "Blueprint Committee" to align its governance and
structure. She served as a member of the Council of the American
Institute of CPAs from 1998 through 2002. She has also been active
in the Denver community, serving on numerous not-for-profit boards
over the years. Ms. Wenzinger received her bachelor's degree from
the University of Northern Colorado in 1972 and was named the
University's Business Alumni of the Year in 2000. About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients. In May 2004, Vicuron received
an approvable letter from the FDA for its lead product
anidulafungin for the treatment of esophageal candidiasis. The
company's other lead product, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections,
has also completed Phase III clinical trials. The company's
versatile research engine integrates industry-leading expertise in
functional genomics, natural products discovery, mechanism-based
drug design and combinatorial and medicinal chemistry. These
approaches are yielding promising novel and next-generation
compounds, many of which are in the later stages of preclinical
development. In addition, the company has research and development
collaborations with leading pharmaceutical companies, such as
Pfizer and Novartis. Forward-Looking Statements This news release
contains forward-looking statements that predict or describe future
events or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties
and other unpredictable factors, many of which are beyond Vicuron's
control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that
clinical trials and the results thereof might be delayed, that the
timing of the filing of any new drug application might be delayed,
that subsequent clinical trials might indicate that a product
candidate is unsafe or ineffective, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that a third party may not be willing to license
our product candidates on terms acceptable to us or at all, that
competitors might develop superior substitutes for their products
or market them more effectively, that a sales force may not be
developed as contemplated and that one or more of its product
candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which
Vicuron is subject. Because of those risks, Vicuron's actual
results, performance or achievements may differ materially from the
results, performance or achievements contemplated by its
forward-looking statement. The information set forth in this news
release represents management's current expectations and
intentions. Vicuron assumes no responsibility to issue updates to
the forward-looking matters discussed in this news release.
DATASOURCE: Vicuron Pharmaceuticals, Inc. CONTACT: Dov A.
Goldstein, M.D. of Vicuron Pharmaceuticals Inc., +1-610-205-2312,
or ; or Hala Bashir of WeissComm Partners, +1-212-204-2080, or , or
Aline Schimmel of Burns McClellan Inc., +1-212-213-0006, or , both
for Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright